Mark Borowsky, MD
Gynecologic Oncology · Newark, DENPI 1871570044
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $15,955 of the $17,333 with a category attached, or 92.0%. 17 manufacturers reported payments, led by Seagen Inc. at 50.4% of the total. Reporting peaked in 2021 at $10,960 and has fallen 98.2% since, to $201 in 2025.
Across 63 payments — averaging $275.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Seagen Inc.$9K
- GSK$5K
- AstraZeneca$2K
- Tesaro, Inc.$400
- Merck$156
- Eisai Inc.$126
- plus $396 from 11 others
Across 1 payment — averaging $27,650 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Karyopharm Therapeutics Inc.$28K
What the payments were for
- Consulting fees$15,95592%
- Travel & lodging$2972%
- Food & beverage$1,0826%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Seagen Inc. | 4 | $8,730 |
| GSK | 14 | $5,381 |
| AstraZeneca | 6 | $2,145 |
| Tesaro, Inc. | 1 | $400 |
| Merck | 9 | $156 |
| Eisai Inc. | 8 | $126 |
| AbbVie | 4 | $63 |
| Myriad Genetic Laboratories, Inc. | 3 | $62 |
| Medtronic | 1 | $50 |
| Johnson & Johnson | 2 | $41 |
| Genmab U.S., Inc. | 2 | $32 |
| Hologic Sales And Service, LLC | 2 | $32 |
| Clovis Oncology, Inc. | 2 | $28 |
| Immunogen, Inc. | 2 | $28 |
| BD | 1 | $23 |
| Novartis | 1 | $22 |
| Pfizer | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few gynecologic oncology providers in Delawareto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other gynecologic oncology in Newark
- Arielle KatcherNewark$2K
- Mark CadungogNewark$205
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.